Yun-Ling Zheng

Dr. Yun-Ling Zheng

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XZXin Zhou
Xin Zhou
CMCatalin Marian
Catalin Marian
KMKepher H. Makambi
Kepher H. Makambi
OKOurania Kosti
Ourania Kosti
BKBhaskar V. S. Kallakury
Bhaskar V. S. Kallakury
YZYun-Ling Zheng
Yun-Ling Zheng
MicroRNAs (miRs) are small, non-protein coding transcripts involved in many cellular functions. Many miRs have emerged as important cancer biomarkers. In the present study, we investigated whether miR levels in breast tumors are predictive of breast cancer local recurrence (LR). Sixty-eight women who were diagnosed with breast cancer at the Lombardi Comprehensive Cancer Center were included in this study. Breast cancer patients with LR and those without LR were matched on year of surgery, age at diagnosis, and type of surgery. Candidate miRs were identified by screening the expression levels of 754 human miRs using miR arrays in 16 breast tumor samples from 8 cases with LR and 8 cases without LR. Eight candidate miRs that showed significant differences between tumors with and without LR were further verified in 52 tumor samples using real-time PCR. Higher expression of miR-9 was significantly associated with breast cancer LR in all cases as well as the subset of estrogen receptor (ER) positive cases (p = 0.02). The AUCs (Area Under Curve) of receiver operating characteristic (ROC) curves of miR-9 for all tumors and ER positive tumors are 0.68 (p = 0.02) and 0.69 (p = 0.02), respectively. In ER positive cases, Kaplan-Meier analysis showed that patients with lower miR-9 levels had significantly better 10-year LR-free survival (67.9% vs 30.8%, p = 0.02). Expression levels of miR-9 and another miR candidate, miR-375, were also strongly associated with ER status (p<0.001 for both). The potential of miR-9 as a biomarker for LR warrants further investigation with larger sample size.

19 June 2009 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
YZYun-Ling Zheng
Yun-Ling Zheng
CAChristine Ambrosone
Christine Ambrosone
CBCelia Byrne
Celia Byrne
WDWarren Davis
Warren Davis
MNMary Nesline
Mary Nesline
SMSusan E. McCann
Susan E. McCann

1 June 2015 in Lung Cancer
Verified
Journal Article
Closed access
BSBing Sun
Bing Sun
YWYing Wang
Ying Wang
KKKrishna Kota
Krishna Kota
YSYaru Shi
Yaru Shi
SMSalaam Motlak
Salaam Motlak
YZYun-Ling Zheng
Yun-Ling Zheng

28 August 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
JMJeanne S Mandelblatt
Jeanne S Mandelblatt
MAMichael H Antoni
Michael H Antoni
TBTraci Bethea
Traci Bethea
SCSteve Cole
Steve Cole
BHBarry I Hudson
Barry I Hudson
MSMina Sedrak
Mina Sedrak
The central premise of this article is that a portion of the established relationships between social determinants of health and racial and ethnic disparities in cancer morbidity and mortality is mediated through differences in rates of biological aging processes. We further posit that using knowledge about aging could enable discovery and testing of new mechanism-based pharmaceutical and behavioral interventions (“gerotherapeutics”) to differentially improve the health of cancer survivors from minority populations and reduce cancer disparities. These hypotheses are based on evidence that lifelong differences in adverse social determinants of health contribute to disparities in rates of biological aging (“social determinants of aging”), with individuals from minoritized groups experiencing accelerated aging (ie, a steeper slope or trajectory of biological aging over time relative to chronological age) more often than individuals from nonminoritized groups. Acceleration of biological aging can increase the risk, age of onset, aggressiveness, and stage of many adult cancers. There are also documented negative feedback loops whereby the cellular damage caused by cancer and its therapies act as drivers of additional biological aging. Together, these dynamic intersectional forces can contribute to differences in cancer outcomes between survivors from minoritized vs nonminoritized populations. We highlight key targetable biological aging mechanisms with potential applications to reducing cancer disparities and discuss methodological considerations for preclinical and clinical testing of the impact of gerotherapeutics on cancer outcomes in minoritized populations. Ultimately, the promise of reducing cancer disparities will require broad societal policy changes that address the structural causes of accelerated biological aging and ensure equitable access to all new cancer control paradigms.

12 February 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
YZYun-Ling Zheng
Yun-Ling Zheng
NHNan Hu
Nan Hu
QSQing Sun
Qing Sun
CWChaoyu Wang
Chaoyu Wang
PTPhilip R. Taylor
Philip R. Taylor
Previous studies showed that chromosomal instability was common in esophageal squamous cell carcinoma (ESCC); however, the mechanisms underlying this instability are unknown. Individuals with deficiencies in telomere maintenance are susceptible to enhanced telomere loss during cell proliferation; such deficiencies could result in telomere dysfunction and genomic instability. We investigated the association between genome-wide chromosomal changes in cancer cells and telomere length/attrition in cancer/stroma cells in 47 ESCC patients. Genome-wide detection of loss of heterozygosity was performed using the Affymetrix GeneChip single nucleotide polymorphism arrays. Telomere length was assessed separately for cancer cells, carcinoma-associated fibroblasts (CAF), infiltrative lymphocytes, and adjacent normal epithelial cells by quantitative fluorescent in situ hybridization using paraffin-embedded sections. Telomere length differed significantly among cell types, such that length in infiltrative lymphocytes > CAFs > cancer cells. Shortened telomeres were observed in cancer cells in 44 of 47 (94%) of the tumors examined. Telomere length in CAFs was significantly associated with chromosomal instability on 4q and 13q and lymphocyte telomere length was significantly associated with instability on chromosomal arms 15q. Although telomere length in cancer cells was not associated with chromosome arm instability, telomere attrition in cancer cells, defined as the telomere length in CAFs minus the telomere length in cancer cells, was significantly associated with chromosomal instability on 13q and 15q. This study provides evidence that telomere shortening is a common genetic alteration in ESCC and that chromosome arm instability is related to both telomere attrition in cancer cells and telomere length in tumor stroma cells. [Cancer Res 2009;69(4):1604–14]

17 June 2009 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
YZYun-Ling Zheng
Yun-Ling Zheng
CLChristopher A. Loffredo
Christopher A. Loffredo
PSPeter G. Shields
Peter G. Shields
SSSahar M. Selim
Sahar M. Selim
Background: Telomere dysfunction is involved in the development of breast cancer and very short telomeres are frequent genetic alterations in breast tumors. However, the influence of telomere lengths of specific chromosomal arms on the breast cancer risk is unknown. Methods: We conducted a case–control study of breast cancer to examine the associations of the telomere length on chromosome 9 short arms (9p) and long arms (9q) with risk of breast cancer. Chromosome 9 arm-specific telomere lengths were measured by quantitative fluorescent in situ hybridization using cultured blood lymphocytes. Results: Telomere length on chromosome 9p was significantly shorter in breast cancer patients than in control subjects ( P < 0.001). Using the 50th percentile value in controls as a cut point, women who have short 9p telomeres had an increased risk of breast cancer [adjusted odds ratio (OR) = 2.6; 95% confidence interval (CI) = 1.5–4.3]. When the 9p telomere length was divided into quartiles, a significant inverse dose–response relationship between 9p telomere length and breast cancer risk was observed ( Ptrend < 0.001), with a quartile ORs of 3.0 (95% CI = 1.2–7.5), 3.9 (95% CI = 1.6–9.5) and 6.6 (95% CI = 2.8–15.9) for third, second and first quartile, respectively, when compared with women in the fourth quartile. Conclusions: Short telomere length on chromosome 9p is strongly associated with the risk of breast cancer. If confirmed by future studies, chromosome 9p telomere length has the potential to be incorporated into the current prediction models to significantly enhance breast cancer risk prediction.